NUVB Nuvation Bio Inc.
Debt Financing ·
Nuvation Bio issued $37.5 million more of its 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters exercised their option in full. The offering now totals $287.5 million, with estimated net proceeds of about $277.6 million, and the notes can be settled in cash, shares or both at the company's choice.
Nuvation Bio's underwriters exercised in full an option for $37.5 million more of 0.75% convertible senior notes due 2032, lifting the offering to $287.5 million. Net proceeds are estimated at $277.6 million, and the capped calls bought with them cost about $2.2 million.
Nuvation Bio plans $200.0 million of notes due 2032 and expects to use the proceeds to repay its senior secured loan and pay for capped calls. The rate and conversion price are not set until pricing.
Nuvation Bio's automatic shelf lets it sell up to $200,000,000 of common stock through Jefferies LLC as sales agent, at up to 3.0% of gross proceeds. The stock last sold at $1.82 on March 4, 2025, and the company's lead drug is still waiting on an FDA decision.
Nuvation Bio is a global oncology company developing therapies with the goal of creating a positive impact on patients' lives. It pursues oncology targets validated by strong clinical or preclinical data and designs novel small molecules that improve on the activity and liabilities of currently marketed drugs. Its product IBTROZI (taletrectinib) was approved by the U.S. Food and Drug Administration on June 11, 2025 for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, and it launched in the United States in June 2025. Taletrectinib is also approved in Japan and China, where partner Nippon Kayaku Co., Ltd. commercializes it as IBTROZI in Japan and partner Innovent Biologics (Suzhou) Co. Ltd. commercializes it as DOVBLERON in China. Taletrectinib continues to be evaluated in two Phase 2 single-arm pivotal studies, TRUST-I in China and TRUST-II globally, and in a confirmatory randomized Phase 3 study against crizotinib. In September 2025, the company enrolled its first patient in TRUST-IV, a global Phase 3 study of taletrectinib as adjuvant treatment for resected ROS1-positive early-stage NSCLC. The filing also includes a table summarizing the company's product candidate pipeline.
| Product or program | What it is | Stage |
|---|---|---|
| IBTROZI (taletrectinib) | Therapy for ROS1-positive non-small cell lung cancer | FDA approved |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $62.9 million | $7.9 million |
| Research and development | $115.1 million | $99.1 million |
| Net income (loss) | -$204.6 million | -$567.9 million |
| Cash from operations | -$173.4 million | -$130.4 million |
| Cash and equivalents | $164.1 million | $35.7 million |
| Short-term investments | $365.1 million | $467.0 million |
Our latest story on this, dated Jul 6, 2026: "Nuvation Bio issues $37.5 million more convertible notes, offering totals $287.5 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 6, 2026: "Nuvation Bio issues $37.5 million more convertible notes, offering totals $287.5 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 6, 2026: "Nuvation Bio issues $37.5 million more convertible notes, offering totals $287.5 million". The story links the filing or release it is based on. Read the story.
Nuvation Bio Inc. trades under the ticker NUVB on NYSE.
Nuvation Bio Inc. is listed on NYSE.
The SEC Central Index Key (CIK) for Nuvation Bio Inc. is 1811063. Its filings are on SEC EDGAR.
351,123,233 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Nuvation Bio Inc. under United States.
Our directory classifies Nuvation Bio Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Nuvation Bio Inc. is US67080N1019.
aibio.space lists Nuvation Bio Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Nuvation Bio is a global oncology company developing therapies with the goal of creating a positive impact on patients' lives. It pursues oncology targets validated by strong clinical or preclinical data and designs novel small molecules that improve on the activity and liabilities of currently marketed drugs.
IBTROZI (taletrectinib): Therapy for ROS1-positive non-small cell lung cancer Stage: FDA approved.
$62.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form 8-K (Items 2.03,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio